JPWO2022071423A1 - - Google Patents
Info
- Publication number
- JPWO2022071423A1 JPWO2022071423A1 JP2022554056A JP2022554056A JPWO2022071423A1 JP WO2022071423 A1 JPWO2022071423 A1 JP WO2022071423A1 JP 2022554056 A JP2022554056 A JP 2022554056A JP 2022554056 A JP2022554056 A JP 2022554056A JP WO2022071423 A1 JPWO2022071423 A1 JP WO2022071423A1
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020165470 | 2020-09-30 | ||
| JP2020165470 | 2020-09-30 | ||
| PCT/JP2021/035941 WO2022071423A1 (ja) | 2020-09-30 | 2021-09-29 | ルミノコッカッセ腸内菌投与による免疫チェックポイント阻害薬の抗腫瘍効果の増強 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPWO2022071423A1 true JPWO2022071423A1 (https=) | 2022-04-07 |
| JP7852863B2 JP7852863B2 (ja) | 2026-04-28 |
Family
ID=80950658
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022554056A Active JP7852863B2 (ja) | 2020-09-30 | 2021-09-29 | ルミノコッカッセ腸内菌投与による免疫チェックポイント阻害薬の抗腫瘍効果の増強 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230364163A1 (https=) |
| EP (1) | EP4223868A4 (https=) |
| JP (1) | JP7852863B2 (https=) |
| CN (1) | CN116322721A (https=) |
| AU (1) | AU2021355240B2 (https=) |
| CA (1) | CA3202362A1 (https=) |
| TW (1) | TW202227611A (https=) |
| WO (1) | WO2022071423A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL312781A (en) * | 2021-11-11 | 2024-07-01 | Microba Ip Pty Ltd | Compositions and methods for treating disease |
| CN116103196B (zh) * | 2022-12-14 | 2023-10-20 | 中国科学院微生物研究所 | 一种活泼瘤胃球菌及其应用 |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018226690A1 (en) * | 2017-06-05 | 2018-12-13 | The University Of Chicago | Microbiome biomarkers of immunotherapy responsiveness: diagnostic, prognostic and therapeutic uses thereof |
| WO2019032572A1 (en) * | 2017-08-07 | 2019-02-14 | Finch Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR DECOLONIZING ANTIBIOTIC-RESISTANT BACTERIA IN INTESTINES |
| WO2019169160A1 (en) * | 2018-02-28 | 2019-09-06 | Evelo Biosciences, Inc. | Compositions and methods for treating cancer using ruminococcus gnavus |
| WO2019191390A2 (en) * | 2018-03-28 | 2019-10-03 | Seres Therapeutics, Inc. | Treatment of a cancer by microbiome modulation |
| JP2020500151A (ja) * | 2016-09-27 | 2020-01-09 | ボード オブ リージェンツ， ザ ユニヴァーシティー オブ テキサス システム | マイクロバイオームをモジュレートすることにより、免疫チェックポイント遮断療法を増強するための方法 |
| JP2020512294A (ja) * | 2016-12-22 | 2020-04-23 | アンスティテュ ギュスタブ ルシ | 抗ｐｄ１／ｐｄ−ｌ１／ｐｄ−ｌ２抗体に対する反応性のマーカーとしての微生物叢組成物と、抗ｐｄ１／ｐｄ−ｌ１／ｐｄ−ｌ２抗体をベースとした治療剤の効果を改善させるための微生物モジュレータの使用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2575978C2 (ru) * | 2010-03-15 | 2016-02-27 | Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания | Система и способ получения и хранения активированных зрелых дендритных клеток |
| CN118340799A (zh) * | 2020-02-27 | 2024-07-16 | 上海上药信谊药厂有限公司 | 抗肿瘤组合物 |
-
2021
- 2021-09-29 CA CA3202362A patent/CA3202362A1/en active Pending
- 2021-09-29 CN CN202180067118.4A patent/CN116322721A/zh active Pending
- 2021-09-29 WO PCT/JP2021/035941 patent/WO2022071423A1/ja not_active Ceased
- 2021-09-29 EP EP21875721.9A patent/EP4223868A4/en active Pending
- 2021-09-29 US US18/029,313 patent/US20230364163A1/en active Pending
- 2021-09-29 TW TW110136270A patent/TW202227611A/zh unknown
- 2021-09-29 JP JP2022554056A patent/JP7852863B2/ja active Active
- 2021-09-29 AU AU2021355240A patent/AU2021355240B2/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020500151A (ja) * | 2016-09-27 | 2020-01-09 | ボード オブ リージェンツ， ザ ユニヴァーシティー オブ テキサス システム | マイクロバイオームをモジュレートすることにより、免疫チェックポイント遮断療法を増強するための方法 |
| JP2020512294A (ja) * | 2016-12-22 | 2020-04-23 | アンスティテュ ギュスタブ ルシ | 抗ｐｄ１／ｐｄ−ｌ１／ｐｄ−ｌ２抗体に対する反応性のマーカーとしての微生物叢組成物と、抗ｐｄ１／ｐｄ−ｌ１／ｐｄ−ｌ２抗体をベースとした治療剤の効果を改善させるための微生物モジュレータの使用 |
| WO2018226690A1 (en) * | 2017-06-05 | 2018-12-13 | The University Of Chicago | Microbiome biomarkers of immunotherapy responsiveness: diagnostic, prognostic and therapeutic uses thereof |
| WO2019032572A1 (en) * | 2017-08-07 | 2019-02-14 | Finch Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR DECOLONIZING ANTIBIOTIC-RESISTANT BACTERIA IN INTESTINES |
| WO2019169160A1 (en) * | 2018-02-28 | 2019-09-06 | Evelo Biosciences, Inc. | Compositions and methods for treating cancer using ruminococcus gnavus |
| WO2019191390A2 (en) * | 2018-03-28 | 2019-10-03 | Seres Therapeutics, Inc. | Treatment of a cancer by microbiome modulation |
Non-Patent Citations (3)
| Title |
|---|
| DATABASE GENBANK [ONLINE], ACCESSION NO. GQ897738.1, 9-MAR-2010 UPDATED: "[retrieved on 27-Oct-2021]", DEFINITION: UNCULTURED BACTERIUM CLONE A3-21 16S RIBOSOMAL RNA GENE, PARTIAL SEQUENCE, JPN6021043437, ISSN: 0005702655 * |
| MICROBIOLOGY TODAY, vol. 33, JPN6023028239, 2006, pages 152 - 155, ISSN: 0005702656 * |
| SYSMEX JOURNAL WEB, vol. 10, no. 2, JPN6023028237, 2009, pages 1 - 12, ISSN: 0005702657 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4223868A1 (en) | 2023-08-09 |
| WO2022071423A1 (ja) | 2022-04-07 |
| JP7852863B2 (ja) | 2026-04-28 |
| US20230364163A1 (en) | 2023-11-16 |
| TW202227611A (zh) | 2022-07-16 |
| EP4223868A4 (en) | 2025-02-12 |
| CN116322721A (zh) | 2023-06-23 |
| AU2021355240A1 (en) | 2023-05-25 |
| CA3202362A1 (en) | 2022-04-07 |
| AU2021355240B2 (en) | 2026-04-16 |
| AU2021355240A9 (en) | 2024-09-26 |
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20230330 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240501 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250430 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20250630 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250813 |
|
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20250901 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20250903 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20250901 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20251007 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20251204 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20251222 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20260310 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20260407 |